2015
DOI: 10.1182/blood-2014-05-576256
|View full text |Cite
|
Sign up to set email alerts
|

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

Abstract: Key Points• KTd is an effective induction and consolidation regimen for transplant-eligible MM patients.• The KTd regimen is safe and well tolerated with a notable lack of peripheral neuropathy. , respectively, and thalidomide 50 mg. Common grade 3/4 adverse events included respiratory (15%), gastrointestinal (12%), and skin disorders (10%); polyneuropathy was infrequent (1%). Complete response rates after induction and consolidation treatment were 25% and 63%, respectively; rates of very good partial response… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
48
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 64 publications
(51 citation statements)
references
References 36 publications
3
48
0
Order By: Relevance
“…92 More recently, carfilzomib combined with lenalidomide (KRd) or thalidomide (KTd) and dexamethasone in NDMM showed similar CR rate (.60%) and PFS between HR and SR patients. 93,94 Recently, favorable responses were observed with monoclonal antibodies against CD38 (daratumumab) or SLAMF7 (elotuzumab) combined with RD in RRMM across cytogenetic subgroups. 95 Consensus statement.…”
Section: Treatment Options For High-risk Diseasementioning
confidence: 99%
“…92 More recently, carfilzomib combined with lenalidomide (KRd) or thalidomide (KTd) and dexamethasone in NDMM showed similar CR rate (.60%) and PFS between HR and SR patients. 93,94 Recently, favorable responses were observed with monoclonal antibodies against CD38 (daratumumab) or SLAMF7 (elotuzumab) combined with RD in RRMM across cytogenetic subgroups. 95 Consensus statement.…”
Section: Treatment Options For High-risk Diseasementioning
confidence: 99%
“…These novel agents in conjunction with risk-adapted treatment strategies and improved supportive therapy have led to an increase in response rates and overall survival in patients with newly diagnosed symptomatic multiple myeloma (NDMM) [1][2][3][4][5][6][7][8][9][10]. In particular, achieving at least a very good partial response (VGPR1) to initial treatment has been shown to translate into increased progression-free and overall survival in these patients [11][12][13].…”
Section: Introductionmentioning
confidence: 99%
“…ՆVGPR rates increased to 76% after auto-transplant and to 89% as best response after four cycles of consolidation therapy signifying that a PI, IMiD, and steroid combination is efficacious. 16 Lenalidomide, a more potent immunomodulatory agent in combination with bortezomib and dexamethasone (RVD) exerted 100% ՆPR rates and ՆVGPR rates of 67%. 17 Deeper responses were seen with less peripheral neuropathy, with the combination of carfilzomib, lenalidomide and dexamethasone (CRD) demonstrating a near complete response (nCR) rate among 62% of the patients in the trial.…”
Section: Novel Combination Therapies In the Induction Settingmentioning
confidence: 99%